# Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

> **NCT02613910** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Pemphigus

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Acetaminophen/paracetamol
- **DRUG:** Antihistamine (cetirizine or equivalent)
- **DRUG:** Prednisone/Prednisolone

## Key facts

- **NCT ID:** NCT02613910
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-23
- **Primary completion:** 2016-03-23
- **Final completion:** 2016-03-23
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613910, "Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02613910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*